Skip to Content
  • Age
  • Title
    Cofounder and CEO
  • Company
    Ginkgo Bioworks

The company’s early investment in automation made it uniquely well equipped to tackle COVID-19 testing needs.  With the support of the National Institutes of Health, Boston-based Ginkgo is building a facility capable of testing 100,000 samples a day, which will open this fall. Kelly has also committed $25 million in resources to COVID-19 projects. As part of that, the company is working closely with Moderna, whose vaccine candidate was one of the first to enter clinical trials, to accelerate the vaccine manufacturing process. As Kelly and Jurassic Park fans know, “Life will find a way.”

Social handles